Stay updated on Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial
Sign up to get notified when there's something new on the Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FMTb6Q2SeDc5iTOSwq8k5ZcBCXBI.uncropped.jpg&w=3840&q=75)
Latest updates to the Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 54 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.3%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has changed from v2.9.3 to v2.9.5, indicating an update or modification to the content of the web page.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the web page.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has recently changed to 'Show less MedlinePlus related topics: Psoriasis Drug Information available for: Apremilast FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Single ( Outcomes Assessor ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Risankizumab Risankizumab 150 mg as a single subcutaneous (SC) injection at at Baseline (Day 1) and Week 4 (Period A) and at Weeks 16, 28, and 40 (Period B). Drug : Risankizumab Subcutaneous injection Other Names: ABBV-066 Skyrizi Experimental : Apremilast Participants receive apremilast 30 mg orally twice daily (BID) in Period A and re-randomized to receive either risankizumab 150 mg as a single SC injection at Weeks 16, 20, 32 in Period B or apremilast 30 mg orally BID from Week 16 up to Week 52 in Period B. For those taking apremilast in Period B, non-responders at Week 28 and Week 40 will be offered to receive risankizumab as rescue medication. Drug : Risankizumab Subcutaneous injection Other Names: ABBV-066 Skyrizi Drug : Apremilast Oral Tablets Other Names: Otezla'SummaryDifference47%
Stay in the know with updates to Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial page.